* Idera Pharmaceuticals reports translational data
supporting the mechanism of action of intratumoral IMO-2125 from
ongoing Phase 1 dose escalation in clinical trial in combination
with ipilimumab in metastatic melanoma patients refractory to
anti-pd-1 trea
Source text for Eikon:
Further company coverage:
Read more
No comments:
Post a Comment